Daraxonrasib trial shows tumors stopped growing in 90% of patients
Daraxonrasib clinical trials for advanced pancreatic cancer showed that tumors stopped growing in 90% of 61 patients. The KRAS inhibitor resulted in a 76.6%…
Menu
Topic
Daraxonrasib clinical trials for advanced pancreatic cancer showed that tumors stopped growing in 90% of 61 patients. The KRAS inhibitor resulted in a 76.6%…